The aim of this study was to evaluate the detection rate of bone metastases and the added value of (11)C-acetate (ACE) positron-emission tomography/computed tomography (PET/CT) compared to bone scintigraphy (BS) in high-risk prostate cancer (PC).
68Ga ligands targeting prostate-specific membrane antigen (PSMA) are rapidly emerging as a significant step forward in the management of prostate cancer. PSMA is a type II transmembrane protein with high expression in prostate carcinoma cells.
In patients treated for prostate cancer, a rising serum prostate-specific antigen (PSA) level is a first sign of relapse, but imaging is needed to determine the localization of the recurrence, which may be local, in lymph nodes, and/or metastatic.
Bone scintigraphy is the standard of reference in bone metastases in prostate cancer patients. However, new radiotracers employed in prostate-specific membrane antigen (PSMA)-ligands has led to the growing importance of PET/CT as diagnostic tool.
To establish the utility of baseline 18F-Fluorocholine (FCH) PET/CT and bone scintigraphy (BS) in the outcome prediction of patients with castration-resistant prostate cancer and bone metastases (CRPC-BM) treated with 223Ra.
The aim of our study was to compare the diagnostic performance of (68)Ga-PSMA PET and (99m)Tc bone scintigraphy (BS) for the detection of bone metastases in prostate cancer (PC) patients.
One hundred twenty-six patients who received planar BS and PSMA PET within three months and without change of therapy were extracted from our database.
Radium-223 is a first-in-class targeted alpha therapy indicated for treating bone metastases from metastatic castration-resistant prostate cancer (mCRPC) without visceral metastases. Imaging plays an important role in the selection of patients eligible for radium-223 therapy.
Objective: We assessed the prognostic value of quantitative indices extracted from bone SPECT-CT to evaluate the response of bone metastatic castrate-resistant prostate cancer (BmCRPC) to abiraterone.
Aim: To investigate the prognostic value of quantitative assessment of skeletal tumor burden on bone scintigraphy (Bone Scan Index) in patients with advanced metastatic castration-resistant prostate cancer (mCRPC) receiving Radium-223-dichloride ((223)RaCl2).
The aim of this study is to assess whether ultra-fast acquisition SPECT/CT (UF-SPECT/CT) can replace standard SPECT/CT (std-SPECT/CT) as "add-on" to whole-body bone scintigraphy (WB-BS) for the investigation of bone metastases.
Login to update email address, newsletter preferences and use bookmarks.